ISO - Certivication

headline-markerStart of the Certainty project on 1st December 2023


Certainty: A virtual twin of cellular immunotherapy for personalized cancer treatment

The Certainity project, launched on December 1, 2023, aims to develop a “virtual twin” in cancer immunotherapy, particularly for CAR T-cell treatments. This digital model integrates a patient’s clinical, molecular and cellular data to simulate disease progression and treatment options, with an initial focus on multiple myeloma. The EU-funded CERTAINTY project, led by Fraunhofer IZI, combines big data, machine learning and computer models to personalize cancer treatment. The project also takes socio-economic factors into account and prioritizes data protection.

Partners of the project:

  • Fraunhofer-Gesellschaft, Germany
      • Fraunhofer IZI (project coordination)
      • Fraunhofer SCAI
      • Fraunhofer IMW
  • University of Leipzig Medical Center, Germany
  • Singleron Biotechnologies GmbH, Germany
  • Collaborate Project Management, Germany
  • Myeloma Patients Europe AISBL, Belgium
  • TriNetX Oncology GmbH, Germany
  • Masaryk University, Czech Republic
  • Information Technology for Translational Medicine, Luxembourg
  • University Hospital of Würzburg, Germany
  • Institut Curie, France
  • University of Namur, Belgium
  • Universitair Medisch Centrum (UMC) Utrecht, The Netherlands
  • Charité – Universitätsmedizin Berlin, Germany
  • European Society for Blood and Marrow Transplantation (EBMT), The Netherlands
  • HealthTree Foundation, USA
  • Roche Pharma AG, Switzerland

Back to News